Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Eichhorst

Showing results (51-60 of 120) with videos related to

Pageof 12
Sort By:
Leukemia & Lymphoma|May 2, 2013
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study GroupPaula Cramer, Anna-Maria Fink, Raymonde Busch, et al.
Oncoimmunology|July 30, 2016
Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiotaNatali Pflug, Sandra Kluth, Jörg J Vehreschild, et al.
Anticancer Research|May 17, 2019
Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical TrialsSotirios Sachanas, Gerassimos A Pangalis, Anna-Maria Fink, et al.
Blood|June 4, 2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutationsPaula Cramer, Eugen Tausch, Julia von Tresckow, et al.
International Journal of Cancer|September 19, 2017
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinibChristine Wolf, Angela Garding, Katharina Filarsky, et al.
Haematologica|August 29, 2015
Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)Paula Cramer, Susanne Isfort, Jasmin Bahlo, et al.
American Journal of Hematology|June 22, 2019
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)Othman Al-Sawaf, Alexandra Bazeos, Sandra Robrecht, et al.
Leukemia & Lymphoma|November 26, 2016
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)Tait D Shanafelt, Sameer A Parikh, Peter A Noseworthy, et al.
The Lancet. Haematology|December 11, 2025
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trialArnon P Kater, Ann Janssens, Herbert Eradat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study GroupGabor Kovacs, Sandra Robrecht, Anna Maria Fink, et al.
Pageof 12

Showing results (51-60 of 120) with videos related to

Sort By:
Pageof 12
Leukemia & Lymphoma|May 2, 2013
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study GroupPaula Cramer, Anna-Maria Fink, Raymonde Busch, et al.
Oncoimmunology|July 30, 2016
Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiotaNatali Pflug, Sandra Kluth, Jörg J Vehreschild, et al.
Anticancer Research|May 17, 2019
Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical TrialsSotirios Sachanas, Gerassimos A Pangalis, Anna-Maria Fink, et al.
Blood|June 4, 2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutationsPaula Cramer, Eugen Tausch, Julia von Tresckow, et al.
International Journal of Cancer|September 19, 2017
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinibChristine Wolf, Angela Garding, Katharina Filarsky, et al.
Haematologica|August 29, 2015
Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)Paula Cramer, Susanne Isfort, Jasmin Bahlo, et al.
American Journal of Hematology|June 22, 2019
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)Othman Al-Sawaf, Alexandra Bazeos, Sandra Robrecht, et al.
Leukemia & Lymphoma|November 26, 2016
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)Tait D Shanafelt, Sameer A Parikh, Peter A Noseworthy, et al.
The Lancet. Haematology|December 11, 2025
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trialArnon P Kater, Ann Janssens, Herbert Eradat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study GroupGabor Kovacs, Sandra Robrecht, Anna Maria Fink, et al.
Pageof 12